Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility of Itraconazole as a Targeted Therapy for Inhibition of Hedgehog Pathway Signaling in Patients With Esophageal Cancer

NCT02749513 is registered in ClinicalTrials.gov with Dallas VA Medical Center as lead sponsor.

NCT NCT02749513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02749513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility of Itraconazole as a Targeted Therapy for Inhibition of Hedgehog Pathway Signaling in Patients With Esophageal Cancer
Lead sponsor
Dallas VA Medical Center
Phase
Phase 1
Overall status
Unknown status
Start date
January 31, 2016
Completion date
October 31, 2022
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer